| Successful Treatment of Sclerosing Encapsulating Peritonitis with Tamoxifen and Prednisolone |
| Ji Yoon Jung, M.D.1, Won Ik Jang, M.D.1, Ji Hyun Yoon, M.D.1, Eui Sik Kim, M.D.1, Sarah Chung, M.D.1, Dae Eun Choi, M.D.1, Ki-Ryang Na, M.D.1, Kang Wook Lee, M.D.1, Dae-Young Kang, M.D.2 and Young-Tai Shin, M.D.1 |
Department of Internal Medicine1 and Pathology2
College of Medicine Chungnam National University, Daejeon, Korea |
| 증례 : 타목시펜과 프레드니솔론으로 호전된 경화성 피막성 복막염 (sclerosing encapsulating peritonitis) |
| 정지윤1, 장원익1, 윤지현1, 김의식1, 정사라1, 최대은1, 나기량1, 이강욱1, 강대영2, 신영태1 |
| 충남대학교 의과대학 내과학교실1, 병리학교실2 |
|
|
| Abstract |
|
Sclerosing encapsulating peritonitis (SEP) is an uncommon but serious complication of long-term peritoneal dialysis (PD). Entrapment of the intestine in fibrous tissue, causing complete intestinal obstruction, is referred to as SEP. The usual clinical presentation is with partial or complete small bowel obstruction, ascites, abdominal mass, or impaired peritoneal ultrafiltration. Conservative treatment carries a poor outcome and surgery has offered variable results. Even though there is no established medical treatment, immunosuppressive drugs, steroid and tamoxifen are often used. Tamoxifen is a nonsteroidal anti-estrogenic drug commonly used in the management of breast cancer. To our knowledge, this is the first case of sclerosing encapsulating peritonitis successfully treated with tamoxifen and prednisolone in Korea. Recently, we have treated three SEP patients with tamoxifen and prednisolone. All three patients showed clinical improvement within a few months. |
| Key Words:
Tamoxifen, Peritonitis, Peritoneal dialysis |
|
PDF Links
Download Citation
